What MedTherapy does

MedTherapy is a Boston-headquartered (Quincy, MA) cell and gene therapy company founded in 2018 that operates an end-to-end, integrated contract development and manufacturing (CDMO) platform for CAR-T cell therapies and viral vectors, alongside a proprietary blood cancer CAR-T product in Phase II clinical trials in India. Its core offering bundles three typically siloed capabilities under one organization — clinical development, CAR-T cell manufacturing, and viral vector manufacturing (lentiviral, retroviral, AAV) — using a proprietary platform that compresses CAR-T production time from the industry-standard 4-6 weeks to as little as one day and reduces per-treatment cost by over 70% compared to US list prices of $400,000+. The technology is enabled by advanced transfection methods in suspension bioreactors and stable cell line-based lentiviral production, executed at a 24,000 sq ft, six-level cGMP facility in Noida, India that currently supports approximately 5,000 patients annually, with a planned Uttar Pradesh expansion targeting 50,000-100,000 patients per year.

The company makes money through two distinct revenue streams: (1) CDMO service contracts with biotech and pharmaceutical companies for clinical and commercial manufacturing of CAR-T cells and viral vectors, priced on a project-quote basis with no publicly disclosed standard rates; and (2) future product revenue from its proprietary CAR-T therapy for blood cancers, which is being developed in-house and commercialized in India through a partnership with Cipla (branding and distribution) with a planned market launch around 2027. Target segments span enterprise biotech/pharma CDMO clients, global academic and research institutions (the company collaborates with 22 institutes across the US, Europe, and Asia), and — via the proprietary pipeline — hematologic cancer patients in India. Go-to-market is enterprise field sales through direct B2B engagement, complemented by channel partners (Cipla for product distribution), event-driven demand generation (ASGCT, CAR-TCR Summit, SITC, J.P. Morgan Healthcare Conference), and academic MoU-based ecosystem development.

The firm is backed by Tata Sons as primary investor, with Harvard-, Novartis-, GSK-, Pfizer-, TATA-, Kite-, and Autolus-experienced executives across leadership, advisory, and board roles (Dr. Bikash Verma as CEO/CMO; Vladimir Slepushkin as CTO; John Anderson as CFO). It remains private, with headcount in the 11-50 range and revenue not publicly disclosed.

Name

MedTherapy

Legal name

MedTherapy Biotechnology Inc.

Website

https://medtherapybiotech.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

MedTherapy is a Boston-headquartered, Tata Sons-backed CDMO founded in 2018 that provides end-to-end CAR-T cell and viral vector manufacturing services globally from India, alongside a proprietary blood cancer CAR-T therapy in Phase II trials targeted for Indian launch in 2027 via Cipla.

Ownership category

akta.pro rank

Product category

Cell & Gene Therapy CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy CDMO (HLAGABAD)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

• Cell therapy CDMO
• Gene therapy manufacturing
• CAR-T cell therapy
• Viral vector production
• Cancer immunotherapy services

Headquarters

HQ city

Quincy

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. CDMO Manufacturing Services: MedTherapy provides contract development and manufacturing (CDMO) services for CAR-T cell therapies and viral vectors to biotech and pharmaceutical partners globally. This includes clinical manufacturing, commercial manufacturing, analytical services, and regulatory support for cell and gene therapy products. Revenue is generated through service contracts with partners.
2. Proprietary CAR-T Therapy Development & Commercialization: MedTherapy develops its own CAR-T cell therapy products in-house and commercializes them through a partnership with Cipla for the Indian market. The company's blood cancer CAR-T therapy is in Phase II clinical trials in India with a planned market launch around 2027.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

MedTherapy is a Boston-based global Cell & Gene Therapy CDMO providing end-to-end, integrated contract development and manufacturing services for CAR-T cell therapies and viral vectors (lentiviral, retroviral, AAV). The company operates cGMP-compliant manufacturing facilities in the USA (Boston/Quincy) and India (New Delhi NCR/Noida) and serves biotech and pharmaceutical partners worldwide. In addition to CDMO services, MedTherapy develops its own proprietary blood cancer CAR-T cell therapy, currently in Phase II clinical trials in India.

Product overview

MedTherapy is an end-to-end, integrated Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) offering three complementary business units: CAR-T cell therapy manufacturing services, viral vector manufacturing services, and proprietary CAR-T cell therapy clinical development. The company operates GMP-grade manufacturing facilities and provides services across clinical and commercial scales for partners and collaborators globally.

Differentiator

Problem solved

Functional benefit

Products and services

• CAR-T Cell CDMO Services End-to-end contract development and manufacturing services for CAR-T cell therapies, providing clinical and commercial-scale GMP production using open, closed, and modular systems with dramatically reduced manufacturing time (as little as one day) and cost (over 70% lower than US prices). Serves biotech and pharmaceutical companies globally with cell therapy candidates advancing through clinical development.
• Viral Vector CDMO Services Contract manufacturing services for critical raw material virus vectors including lentiviral, retroviral, and adeno-associated viral (AAV) vectors used in CAR-T cell therapies. Includes stable packaging and producer cell lines, adherent and suspension cultures, end-to-end development, cGMP manufacturing and analytics, and cost-effective processes. Serves biotech and pharma partners globally.
• Proprietary Blood Cancer CAR-T Cell Therapy MedTherapy's proprietary CAR-T cell therapy for blood cancer treatment, featuring one-day manufacturing capability and approximately 70% cost reduction compared to conventional US therapies (which can exceed $400,000 per treatment). Currently in Phase II clinical trials in India and planned for market launch in India around 2027 via Cipla partnership. Targets lymphoma, leukemia, and solid tumors (with armoured CAR-T approaches).

Quantifiable outcome

• Manufacturing time reduced from 4-6 weeks to as little as 1 day
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core, strategic and minor.

• CiplacoreChannel Partner/ Reseller/ Distributor · 27 May 2026MedTherapy has partnered with Cipla for commercialization of its blood cancer CAR-T therapy in India. Cipla handles branding and distribution of the therapy once regulatory approvals are secured. The therapy is currently in Phase II clinical trials in India, with a planned market launch around 2027.
• Sharda UniversitystrategicStrategic or Co-development Partner · 16 April 2025MedTherapy signed a Memorandum of Understanding (MoU) with Sharda University marking a strategic collaboration aimed at advanced research, innovation, and talent development in the field of Cancer Gene Therapy. The partnership includes joint research, internship programs, and training opportunities.
• National Institute of Immunology (NII)strategicStrategic or Co-development PartnerMedTherapy signed a collaborative agreement with the National Institute of Immunology, New Delhi, for scientific exchange and developmental activities in Immuno-Oncology and associated applications including CAR-T targeting solid tumours.
• Shiv Nadar UniversityminorStrategic or Co-development PartnerMedTherapy is exploring synergy with Shiv Nadar University for the advancement of Science and Technology, discussions centered on potential research and academic collaboration.
• Amity UniversityminorStrategic or Co-development PartnerMedTherapy is exploring synergy with Amity University's Molecular Medicine & Stem Cell Research department, discussing potential collaboration in the field of cell and gene therapy research.
• Government Institute of Medical Sciences (GIMS)minorStrategic or Co-development PartnerMedTherapy team met with the Director of GIMS, Dr. Saurabh Srivastava, to discuss collaboration for scientific exchange and developmental activities.
• Patanjali GroupminorStrategic or Co-development PartnerMedTherapy team engaged with Shri Acharya ji of Patanjali Group to discuss scientific developments in Gene Therapy and Innovations.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Cellares: Cell therapy manufacturing automation platform/CDMO competitor focused on industrialized CAR-T cell production. Daniel Weinstein, MedTherapy's Director of Business Development, previously held a senior BD role at Cellares, underscoring direct competitive and talent overlap.
• Kite Pharma (Gilead): A division of Gilead Sciences that pioneered commercial CAR-T cell therapy manufacturing (Yescarta, Tecartus). Direct overlap with MedTherapy on autologous CAR-T cell therapy manufacturing, scale, and viral vector supply, though at much larger commercial scale.
• WuXi Advanced Therapies (WuXi AppTec): Global cell and gene therapy CDMO with commercial-scale viral vector (LV, AAV) and cell therapy manufacturing capacity. Direct competitor for CAR-T CDMO contracts, particularly for partners seeking large-scale international capacity and cost competitiveness similar to what MedTherapy markets.
• PCT/Minaris Advanced Therapies: A dedicated cell and gene therapy CDMO (formerly PCT Cell Therapy) offering process development and GMP manufacturing for CAR-T and other cell therapies — same exact target customer and service line as MedTherapy's CDMO business; Daniel Weinstein also previously worked there.
• Autolus Therapeutics: Clinical-stage CAR-T company with in-house viral vector manufacturing capabilities and a founding team including CAR-T pioneer Martin Pule (also a MedTherapy advisor). Autolus and MedTherapy both develop proprietary CAR-T therapies while running internalised vector/cell manufacturing, making them structurally comparable.

Emerging players

• Ori Biotech: Cell and gene therapy manufacturing automation platform serving CDMOs and developers with proprietary bioreactor and process-automation technology. Adjacent competitor focused on enabling next-generation manufacturing throughput that overlaps MedTherapy's technology-differentiation thesis.

Broad incumbents

• Lonza Cell & Gene Technologies: World's largest contract development and manufacturing organization with a dedicated Cell & Gene Technologies business that offers viral vector and cell therapy GMP manufacturing at commercial scale globally. Broader portfolio than MedTherapy but directly competes for CAR-T and viral vector CDMO contracts.
• Charles River Laboratories: Large CRO/CDMO with a Cell & Gene Therapy division offering viral vector and cell therapy development and manufacturing. Overlaps with MedTherapy's clinical-grade and commercial-grade viral vector and cell therapy services, though as one segment of a much broader scientific services portfolio.
• Catalent: Major global CDMO with established cell therapy services (including through its Paragon, MaSThera, and previously Cellular Medicine acquisitions). Provides clinical and commercial manufacturing of viral vectors and cell therapies, overlapping directly with MedTherapy's service offerings.
• Novartis (Cell & Gene Therapy Unit): Launched the first FDA-approved CAR-T therapy (Kymriah) and operates large-scale CAR-T cell manufacturing. Founder/leadership of MedTherapy includes former Novartis executives, and the companies compete in both proprietary CAR-T products and contracted manufacturing capability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedTherapy